Efek Pemberian Kombinasi Siprofloksasin dan A-Mangostin Secara In Vitro Terhadap Eradikasi Uropatogen Escherichia Coli

Maya Dian Rakhmawatie(1*), Afiana Rohmani(2)

(1) FK UNIMUS, Semarang
(2) FK UNIMUS, Semarang
(*) Corresponding Author


Background: The percentage of resistance Escherichia coli (E. coli) in patients with UTI to ciprofloxacin reached 73.04%. Various attempts to maximize the use of antibiotics have been done, including optimizing the parameters pharmacokinetics/pharmacodynamics (PK / PD) of each antibiotic. Another effort is needed to optimize the use of antibiotic treatment that has been available, one of which combines the use of compounds derived from herbs, eg active compounds a-mangostin.
Objective: The purpose of this study is to find the effect of the combination of á-mangostin and ciprofloxacin on uropathogen E. coli (UPEC) eradication.
Methods: This research was carried out by treating the bacteria uropathogenE. coli (UPEC) in vitro. Treatment is divided into (a) treatment groups using ciprofloxacin concentration Cmax at 500 mg dose (2,4 μg/mL), (b) treatment groups using ciprofloxacin concentration Cmax at 750 mg dose (4,3 μg/mL), (c) treatment groups using ciprofloxacin concentration 2,4 μg/mL and a-mangostin concentration 0,18 μg/mL, (d) treatment groups using ciprofloxacin concentration 4,3 μg/mL and a-mangostin concentration 0,18 μg/mL.
Result: states that a combination of á-mangostin and ciprofloxacin can prevent the growth of uropathogen E. coli ciprofloxacin-resistant strains (MIC value of 128 μg/mL) compared to administration of ciprofloxacin alone, but the effect was not significant. On uropathogen E coli sensitive to ciprofloxacin (MIC 0,008 μg/mL) and intermediate (MIC 0,5 μg/mL), there was no difference effect of decreasing the number of colonies between awarding a combination of ciprofloxacin and á-mangostin compared administering ciprofloxacin only.
Conclusion: Provision of á-mangostin grading 0,18 μg/mL combined with ciprofloxacin had no real benefit in eradicating uropathogen E. coli, which is tested in vitro.


ciprofloxacin; a-mangostin; uropathogen; E. coli

Full Text:



Drussano, G.L. 2007. Pharmacokinetics andpharmacodynamics of antimicrobial.Clin Infect Dis.45:589-595.

Hooton, TM. 2000. Pathogenesis of urinary trackinfections: an update.Journal of antimicrobialchemotherapy 46. Suppl. S1:1-7

Mandal J, Acharya S, Buddhapriya D, Parija SC.2012. Antibiotic resistance pattern among commonbacterial uropathogens with a special reference tociprofloxacin resistantEscherichia coli.

Gloede, J., Scheerans, C., Derendorf, H., and Kloft,C. 2010.In vitro pharmacodynamic models todetermine the effect of antibacterial drugs.JAntimicrob Chemother 65:186-201.

Rakhmawatie MD, Mustofa. 2012. Efek perbedaandosis siprofloksasin pada resistensi uropatogenEscherichia coli: simulasi model kinetika in vitro.Tersedia dalam etd.ugm.ac.id.

Olofsson, S.K., Marcusson, L.L., Stromback, A.,Hughes, D., and Cars, O. 2007. Dose related selectionof fluoroquinolone resistant escherichia coli.JAntimicrob Chemother 60:795-801.

Howell AB., Botto H., Combescure C., Blanc-PottardA., Gausa L., Matsumoto T., et al. 2010. Dosageeffect on uropathogenicEscherichia coli anti-adhesion activity in urine following consumption ofcranberry powder standardized for proanthocyanidincontent: a multicenteric randomized double blindstudy.BMC (Biomedcentral) Infectious DiseaseVol.10:94

Chaverri JP, Rodriguez NC, Ibarra MO, and RojasJMP. 2008. Review Medicinal properties ofmangosteen (Garcinia mangostana).Food andChemical Toxicology Vol. 46: 3227-3239

Allou, N., Cambau, E., Massias, L., Chau, F., andFantin, B., 2009. Impact of low-level resistance tofluoroquinolones due to qnrA1 and qnrS1 genes ora gyrA mutation on ciproûoxacin bactericidal activityin a murine model ofEscherichia coli urinary tractinfection.Antimicrob Agents Chemother 53(10):4292-4297.

Koh JJ, Qiu S, Zou H, LakshminarayananR, Li J,Zhou X, et al. 2013. Rapid bactericidal action ofalpha-mangostin against MRSA as an outcome ofmembrane targeting.Biochimica et Biophysica ActaVol 1828(2): 834-44

EUCAST. 2012. Breakpoint tables for interpretationof MIC and zone diameters. European Committee onAntimicrobial Susceptibility Testing. Diakses 11Maret 2012 dari www.eucast.org/clinical_breakpoints/

CLSI. 2012. Methods for dilution antimicrobialsusceptibility test for bacteria that grow aerobically;approved standard ninth edition. CLSI M07-09 Vol.32(2).

Chitchumroonchokchai C, Riedl KM, Suksumrarn S,Clinton SK, Kinghorn AD, and Faila ML. 2012.Xanthones in mangosteen juice are absorbed andpartially conjugated by healthy adults.Journal ofNutrition Vol 142(4): 675-680

FDA. 2011. Ciprofloxacin. Ciprofloxacin Official FDAInformation, Side Effect, and Uses. Diakses 15September 2011 darihttp://www.drugs.com/pro/ciprofloxacin.html

Fardiaz, S. 1992. Mikro pangan I. Jakarta: PT.Gramedia Pustaka.

Van der Horst, MA., Schuurmans, JM., Smid, MC.,Koenders, BB., and ter Kuile, BH. 2011. De novoacquisition of resistance to three antibiotic byEscherichia coli.Microb. Drug Resist, Vol. 17(2):141-7

Ibrahim NHS, Taher M, Susanti D, AmroudineMZAM, dan Ahmed QU. 2014. Direct and indirectantimicrobial effects of á-mangostin on pathogenicmicroorganism.Journal of Coastal Life Medicine,Vol. 2(1): 70-5

Ibrahim MY, Hashim NM, Mariod AA, Mohan S,Abdulla MA, Abdelwahab SI, dan Arbab IA. 2014.Review: á-mangostin from Garcinia mangostana Linn:An updated review of its pharmacological properties.

Article Metrics

Abstract view : 704 times
PDF - 241 times

DOI: https://doi.org/10.26714/magnamed.1.2.2015.191-199


  • There are currently no refbacks.

Indexed by




Creative Commons License

MAGNA MEDIKA by APKKM is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.